Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Ayala Pharmaceuticals Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations May 09, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome March 26, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS IMNM Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors February 20, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS IMNM Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals February 06, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS IMNM Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors November 06, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 October 23, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Announces Closing of Merger with Biosight October 19, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update August 10, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023 August 01, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement July 27, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors July 05, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting June 05, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting May 25, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update May 23, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting April 27, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee March 03, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022 February 10, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting November 17, 2022 From Ayala Pharmaceuticals Via GlobeNewswire Tickers AYLA Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors November 16, 2022 From Ayala Pharmaceuticals Via GlobeNewswire Tickers AYLA Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 04, 2022 From Ayala Pharmaceuticals Via GlobeNewswire Tickers AYLA Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement October 19, 2022 From Ayala Pharmaceuticals Via GlobeNewswire Tickers ADXS AYLA Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors September 29, 2022 From Ayala Pharmaceuticals Via GlobeNewswire Tickers AYLA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.